Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOTREM in septic shock
NL-OMON45445Phase 2Active, not recruiting
- Sponsor
- Inotrem
- Start
- Oct 2017
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of nangibotide in septic shock and sepsis (4 arms), sponsored by Inotrem. Primary endpoint: Safety and tolerability. Started Oct 2017; status: active, not recruiting.
02
Drugs
nangibotide
03
Conditions
septic shocksepsis
Beyond the preview
Go deeper on NL-OMON45445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45445.